A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
SepsisMacrophage Activation Syndrome
Interventions
DRUG

Anakinra

Treatment with anakinra

DRUG

Recombinant human interferon-gamma

Treatment with recombinant human interferon-gamma

DRUG

Placebo

Treatment with Placebo

Trial Locations (13)

11527

1st Department of Pulmonary Medicine and Intensive Care Unit, Athens

12462

2nd Department of Critical Care Medicine, Athens

4th Department of Internal Medicine, Athens

14561

Intensive Care Unit, Center for Accident Rehabilitation (KAT) of Athens, Athens

18536

"Intensive Care Unit, Tzanio Piraeus General Hospital", Piraeus

19600

"Intensive Care Unit, Latsio, Thriasio Elefsis General Hospital", Elefsina

26504

Department of Internal Medicine, Patras University Hospital, Pátrai

41221

"Intensive Care Unit, Koutlimbaneio & Triantafylleio Larissa General Hospital", Larissa

41334

Department of Internal Medicine, Larissa University Hospital, Larissa

45500

Intensive Care Unit, Ioannina University Hospital, Ioannina

54634

"Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital", Thessaloniki

54635

"Intensive Care Unit, G.Gennimatas Thessaloniki General Hospital", Thessaloniki

68100

Intensive Care Unit, Alexandroupolis University Hospital, Alexandroupoli

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER

NCT03332225 - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis | Biotech Hunter | Biotech Hunter